ResearcherBioNTech SEActive in the last 2 years
BioNTech Responsible Person
Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.
Their work
- Papers
- 0
- Trials
- 9
- Grants
- 0
- Labs led
- 0
- Collaborators
- 0
2016: 2 trials · 2017: 1 trial · 2018: none · 2019: none · 2020: 1 trial · 2021: none · 2022: 1 trial · 2023: none · 2024: 1 trial · 2025: 3 trials
Trials 9
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investig… Study director NCT07070232↗
- A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor… Study director NCT07186842↗
- A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been T… Study director NCT07255404↗
- Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma Study director NCT06069778↗
- Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pan… Study director NCT04683939↗
- Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Study director NCT04101357↗
- Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy Study director NCT03118349↗
- Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies Study director NCT02672917↗
- Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 Study director NCT02687230↗
Closest collaborators
No collaborators recorded.
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.